Analysts on Wall Street Lower Ratings for These 5 Stocks

Page 5 of 5

01. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Price Reaction after the Downgrade: -40.34 (-37.47%)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology firm that seeks to leverage gene therapies to treat serious diseases. Cambridge, Massachusetts-based Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a global biotechnology company focused on the development of precision genetic medicine for rare diseases. Driven by its multi-platform precision genetic engine, the company currently has a pipeline of more than 40 programs in various stages of development across Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and other rare diseases. Oppenheimer recently downgraded Sarepta Therapeutics (SRPT) from Outperform to Market Perform, a decision likely influenced by the disappointing outcome of the EMBARK study, which missed its primary endpoint. The latest market data reveals Sarepta Therapeutics’ current stock price at $67.31, reflecting a significant decrease of 37.5% following the downgrade. The downgrade by Oppenheimer suggests a reevaluation of their previous positive outlook on Sarepta Therapeutics, driven by the unfavorable results of the EMBARK study.

See also 20 Biggest American Food Exports in Recent Years and Michael Jordan and 10 Richest Black Americans.

Page 5 of 5